Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 2/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.46 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL919897 | 0.95 | MAOA (0.56) | HTR2ASIGMAR1MAOAMAOBL3MBTL1 | |
| SCHEMBL687989 | 0.93 | SIGMAR1 (0.56) | SIGMAR1MAOAMAOBL3MBTL1 | |
| SCHEMBL8939756 | 0.93 | SIGMAR1 (0.56) | SIGMAR1MAOAMAOBL3MBTL1 | |
| SCHEMBL158694 | 0.90 | MAOA (0.50) | HTR2ASIGMAR1MAOAMAOBSMN1; SMN2 | |
| SCHEMBL9863991 | 0.87 | MAOB (0.54) | HTR2AMAOAMAOBHDAC1SMN1; SMN2 | |
| SCHEMBL27498097 | 0.87 | MAOA (0.48) | HTR2ASIGMAR1MAOAMAOBSMN1; SMN2 | |
| SCHEMBL11803736 | 0.84 | MAOA (0.40) | HTR2ASIGMAR1MAOAMAOBSLC6A3 | |
| SCHEMBL54347 | 0.84 | HTR2A (0.70) | HTR2ASIGMAR1MAOAMAOBIDO1 | |
| SCHEMBL11690401 | 0.81 | SIGMAR1 (0.41) | HTR2ASIGMAR1MAOAMAOBSLC6A3 | |
| SCHEMBL9069707 | 0.81 | HTR2A (0.75) | HTR2ASIGMAR1MAOAMAOBIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | DONG-A ST CO., LTD. (KR) | 2024-01-25 | — | — | US | claimed |
| WO-2024009215-A1 | NOVEL COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | DONG-A ST CO., LTD. (KR) | 2024-01-11 | — | — | WO | claimed |
| US-20180033965-A1 | NOVEL DIAMINE COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE USING THE SAME | E-RAY OPTOELECTRONICS TECHNOLOGY CO., LTD. (TW) | 2018-02-01 | — | — | US | claimed |
| CN-103221047-A | Compounds and methods | TEMPERO PHARMACEUTICALS INC | 2013-07-24 | — | — | CN | claimed |
| WO-2008104756-A1 | UREA DERIVATIVES AND THEIR THERAPEUTIC USE | SERENTIS LIMITED (GB) | 2008-09-04 | — | — | WO | claimed |
| US-11997917-B2 | Quantum dot electroluminescence device | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2024-05-28 | — | — | US | disclosed |
| US-20240114765-A1 | QUANTUM DOT ELECTROLUMINESCENCE DEVICE | SAMSUNG ELECTRONICS CO LTD (KR) | 2024-04-04 | — | — | US | disclosed |
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | DONG-A ST CO., LTD. (KR) | 2024-01-25 | — | — | US | disclosed |
| WO-2024009215-A1 | NOVEL COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | DONG-A ST CO., LTD. (KR) | 2024-01-11 | — | — | WO | disclosed |
| EP-3751631-B1 | POLYMER MATERIAL, MATERIAL FOR ELECTROLUMINESCENCE DEVICE, LIQUID COMPOSITION, THIN FILM, AND ELECTROLUMINESCENCE DEVICE | SAMSUNG ELECTRONICS CO LTD (KR) | 2023-12-13 | — | — | EP | disclosed |
| US-11758800-B2 | Polymer material, material for electroluminescence device, liquid composition, thin film, and electroluminescence device | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2023-09-12 | — | — | US | disclosed |
| US-20230139979-A1 | ORGANIC AMINE COLLECTION METHOD | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2023-05-04 | — | — | US | disclosed |
| WO-1998013355-A1 | HETEROCYCLIC ESTERS AND AMIDES | GUILFORD PHARMACEUTICALS INC. (US) | 1998-04-02 | — | — | WO | disclosed |
| EP-0805796-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 1997-11-12 | — | — | EP | disclosed |
| WO-1997016190-A1 | ROTAMASE ENZYME ACTIVITY INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1997-05-09 | — | — | WO | disclosed |
| WO-1996022966-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 1996-08-01 | — | — | WO | disclosed |
| EP-0514332-B1 | Bis-phosphites | CIBA GEIGY AG (CH) | 1996-04-17 | — | — | EP | disclosed |
| US-5308902-A | Heterocyclic fused ring structures, stabilizers for PVC and polyolefins | CIBA-GEIGY CORPORATION (US) | 1994-05-03 | — | — | US | disclosed |
| EP-0514332-A1 | Bis-phosphites | CIBA-GEIGY AG (CH) | 1992-11-19 | — | — | EP | disclosed |
| EP-0058740-B1 | IMPROVED POLYESTER MOLDING COMPOSITIONS AND MOLDED ARTICLES PRODUCED THEREFROM | UNION CARBIDE CORPORATION (US) | 1985-05-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180033965-A1 | NOVEL DIAMINE COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE USING THE SAME | OR10J3, AOC1, SAT1 | HTR2A 2906/4885SIGMAR1 1100/4885MAOA 877/4885 |
| US-20230139979-A1 | ORGANIC AMINE COLLECTION METHOD | H1-0, F12, C1S | HTR2A 1639/4885SIGMAR1 1054/4885MAOA 89/4885 |
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | EIF2AK4, GCN1, GCGR | HTR2A 2687/4885SIGMAR1 3330/4885MAOA 2614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.